Lansoprazol Stada

Lansoprazole, the active ingredient in Lansoprazol Stada, is a proton pump inhibitor presented as an oral dosage form for systemic use. It reduces gastric acid production and is used to treat conditions such as gastro‑esophageal reflux disease, peptic ulcer disease and Zollinger‑Ellison syndrome in adults.

GNH USA supplies Lansoprazol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion in several acid‑related disorders. - Gastro‑esophageal reflux disease (GERD): alleviates heartburn and esophageal irritation by maintaining higher gastric pH. - Peptic ulcer disease: promotes ulcer healing by decreasing acid exposure to the gastric and duodenal mucosa. - Helicobacter pylori eradication regimens: used in combination therapy to enhance eradication rates by suppressing acid. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors.

Lansoprazole may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools, often transient. - Nausea: feeling of stomach upset. - Abdominal pain: discomfort in the upper abdomen.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Clostridioides difficile infection: persistent diarrhea, abdominal pain. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat.

When prescribing lansoprazole, clinicians should consider several safety aspects. - Assess renal function: dose adjustment may be needed in severe renal impairment. - Monitor for osteoporosis: long‑term therapy may affect calcium absorption. - Use with caution in elderly: higher risk of fractures and electrolyte disturbances. - Avoid concomitant use with drugs requiring gastric acidity for absorption unless medically indicated. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Lansoprazole can alter the pharmacokinetics of several medicines.

Major Interactions (Avoid): - Ketoconazole or itraconazole: reduced antifungal absorption due to increased gastric pH. - Atazanavir: decreased antiviral efficacy from impaired absorption. - Clopidogrel: reduced antiplatelet effect due to CYP2C19 inhibition.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, monitor coagulation. - Digoxin: altered serum levels, monitor for toxicity. - Methotrexate: increased exposure, monitor renal function.